ERBB2 and breast carcinoma: Multi-gene genomic assays such as Oncotype DX, MammaPrint, PAM50, EndoPredict, and the Breast Cancer Index have been implemented to stratify the recurrence risk and assist the decision of chemotherapy treatment in ER+/HER2- early-stage breast cancer patients.